| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human SILV/PMEL recombinant protein (Position: H182-Q5565) was used as the immunogen for the PMEL antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
PMEL Antibody / Premelanosome protein / SILV is a anti-PMEL Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as ELISA, Flow cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (IHC), Western blot (WB) with listed reactivity in Human, Mouse, Rat. Reported localization: Cytoplasm.
Key elements and design rationale
- Target: PMEL
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): ELISA, FACS, IF, IHC, WB
Biological background
Functionally, PMEL antibody identifies a 661-amino-acid type I transmembrane glycoprotein synthesized in melanocytes. PMEL is cleaved by proprotein convertases into M alpha and M beta fragments, which assemble into amyloid fibrils in stage II melanosomes. These fibrils provide a matrix for eumelanin deposition, enabling proper pigment granule maturation.
The PMEL gene is located on chromosome 12p13.31 and is expressed exclusively in pigment-producing cells, including melanocytes and retinal pigment epithelium. PMEL expression is regulated by the transcription factor MITF and is upregulated during melanocyte differentiation. It plays a central role in pigment biogenesis and melanosome architecture.
Pathologically, PMEL is a target antigen in melanoma immunotherapy and an established marker for melanocytic tumors. Mutations in PMEL can cause pigment dilution phenotypes in animals due to altered fibril formation. Research using PMEL antibody supports studies in pigmentation biology, melanoma diagnostics, and organelle structure.
PMEL antibody is validated for immunohistochemistry, western blotting, and immunofluorescence to detect melanosomal structural proteins.
Structurally, Premelanosome protein contains an N-terminal signal peptide, a polycystic kidney disease-like (PKD) domain, and a transmembrane domain. Its cleaved fragments aggregate to form functional amyloid fibrils. This antibody supports detailed examination of PMEL's role in melanosome assembly and pigmentation control.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- Immunofluorescence: visualize subcellular distribution and cell-to-cell heterogeneity.
- Immunohistochemistry: map target signal in tissue context and compare regions/phenotypes.
- Flow cytometry: quantify target-positive populations and signal shifts at single-cell resolution.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
